Advances in targeting cell surface signalling molecules for immune modulation

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

B7RP-1 Blockade Ameliorates Autoimmunity through Regulation of Follicular Helper T Cells

(2014) Y.-L. Hu et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway

(2011) Y. Sakoda et al.   BLOOD

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

4-1BB signaling beyond T cells

(2011) Dass S Vinay et al.   Cellular & Molecular Immunology

B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response

(2011) D. Quandt et al.   CLINICAL CANCER RESEARCH

Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules

(2011) A M Azimzadeh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Early Treatment of NOD Mice With B7-H4 Reduces the Incidence of Autoimmune Diabetes

(2011) X. Wang et al.   DIABETES

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

B7-H2 Is a Costimulatory Ligand for CD28 in Human

(2011) Sheng Yao et al.   IMMUNITY

Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model

(2011) Yuwen Zhu et al.   IMMUNITY

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Host APCs Augment In Vivo Expansion of Donor Natural Regulatory T Cells via B7H1/B7.1 in Allogeneic Recipients

(2011) T. Yi et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

(2011) D. B. Flies et al.   JOURNAL OF IMMUNOLOGY

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice

(2010) Tamami Sakanishi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

(2010) T. Doi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer

(2010) Jingting Jiang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

TRAIL receptor signaling and therapeutics

(2010) Junaid Abdulghani et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The CD4-like molecule LAG-3, biology and therapeutic applications

(2010) Sophie Sierro et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression

(2010) Jörn C. Albring et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CD137-Mediated Pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic Mice

(2010) J. Wang et al.   JOURNAL OF IMMUNOLOGY

Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis

(2010) Takaaki Arigami et al.   JOURNAL OF SURGICAL ONCOLOGY

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

(2010) Elias A Said et al.   NATURE MEDICINE

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management

(2010) Katharina C. Kaehler et al.   SEMINARS IN ONCOLOGY

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

(2010) Christian P. Larsen et al.   TRANSPLANTATION

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

PD-1 on dendritic cells impedes innate immunity against bacterial infection

(2009) S. Yao et al.   BLOOD

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

(2009) C. Brignone et al.   CLINICAL CANCER RESEARCH

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Integrating costimulatory agonists to optimize immune-based cancer therapies

(2009) Angela D Pardee et al.   Immunotherapy

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells

(2009) S.-W. Lee et al.   JOURNAL OF IMMUNOLOGY

Small-molecule costimulatory blockade: organic dye inhibitors of the CD40–CD154 interaction

(2009) Emilio Margolles-Clark et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data

(2009) Takeshi Azuma et al.   PLOS MEDICINE

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

(2008) James O. McNamara et al.   JOURNAL OF CLINICAL INVESTIGATION

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

(2008) Silvia Piconese et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY